Swedish Orphan Biovitrum AG

Sobi is an international biopharmaceutical company focused on providing access to innovative treatments for rare diseases. Main therapeutic areas of the international company with presence in more than 30 countries are haematology and immunology. Within Haematology, Sobi is a leading company in haemophilia and also provides a treatment for thrombocytopenia, a condition characterised by abnormally low levels of platelets in the blood. In the field of immunology Soby has gained extensive experience over many years, which led to the development of three strongly growing products that each meet high unmet medical needs and therefore to the treatment of serious, disabling or even life-threatening diseases. Last but not least, Sobi also provide important specialty treatments in the area of genetics and metabolism. Sobi is a biopharmaceutical company with in-house capabilities that stretch from late-stage R&D, biologics manufacturing and supply, to patient access and distribution.